King Rachel K.

SEC source: 0001193125-26-294691 · ownership.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2036-06-29

F1 · derivative.exercise_date: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001104659-26-076928 · tm2618639-7_4seq1.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,880 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date

F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date

SEC source: 0001104659-26-076928 · tm2618639-7_4seq1.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,070

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

SEC source: 0001104659-26-076928 · tm2618639-7_4seq1.xml · derivative · entry 3

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,180

Underlying: Common Stock · 14,180 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001104659-26-076928 · tm2618639-7_4seq1.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,270

Underlying: Common Stock · 21,270 shares

Expires 2036-06-18

F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0000950170-25-091585 · ownership.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2035-06-25

F1 · derivative.exercise_date: This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001104659-25-062194 · tm2518838-4_4seq1.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,884

Underlying: Common Stock · 18,884 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001104659-25-062194 · tm2518838-4_4seq1.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,326

Underlying: Common Stock · 28,326 shares

Expires 2035-06-20

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001593968-25-000760 · primary_01.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,420 shares

Expires 2034-06-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-25-000760 · primary_01.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,190

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-25-000011 · primary_01.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,770

SEC source: 0000950170-24-127074 · ownership.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-11-11

F1 · derivative.exercise_date: This option was granted on November 12, 2024 and is scheduled to vest in equal monthly installments until November 12, 2027, subject to continued service.

SEC source: 0001593968-24-000862 · primary_01.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,420

Underlying: Common Stock · 10,420 shares

Expires 2034-06-12

SEC source: 0001593968-24-000862 · primary_01.xml · derivative · entry 3

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,630

Underlying: Common Stock · 15,630 shares

Expires 2034-06-12

SEC source: 0001593968-24-000862 · primary_01.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,670 shares

Expires 2033-06-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-24-000862 · primary_01.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-011863 · form4-05012024_080549.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-009743 · form4-04022024_040411.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 515,194

F1 · shares: These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $10,000.

SEC source: 0001209191-24-000068 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,860

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $10,000.

SEC source: 0001209191-23-051390 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 507,622

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board retainer fees of $10,000.

SEC source: 0001209191-23-036748 · doc4.xml · derivative · entry 6

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,670

Underlying: Common Stock · 6,670 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F5 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.

F5 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-23-036748 · doc4.xml · derivative · entry 5

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,710

Underlying: Common Stock · 7,710 shares

Expires 2033-06-12

F4 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Plan will vest one (1) year from the June 12, 2023 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-23-036748 · doc4.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-23-036748 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

SEC source: 0001209191-23-031465 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-05-18

F1 · derivative.exercise_date: The shares underlying this option vest on May 19, 2024, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001209191-23-007267 · doc5.xml · nonDerivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By RBK LLC

Disclosed balance after: 7,500

F3 · ownership.nature: The reporting person is co-manager of this entity. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

SEC source: 0001209191-22-038593 · doc4.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 700 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-22-038593 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

SEC source: 0001209191-22-036753 · doc4.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,100

Underlying: Common Stock · 3,100 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-22-036753 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2032-06-10

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 10, 2022 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-22-030999 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2032-05-17

F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001209191-23-007267 · doc5.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,955

F1 · balance_after: Includes 48,125 shares underlying restricted stock units held as of the date of this report. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2 · balance_after: This total also includes 37,000 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the reporting person on February 25, 2021 and are now owned directly by the reporting person.

SEC source: 0001209191-21-043702 · doc4.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 25, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 25, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-21-043702 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

SEC source: 0001209191-21-052810 · doc4a.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,450

Underlying: Common Stock · 3,450 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F1 · shares: This amendment to the original Form 4 filed on June 29, 2021 is being filed to correct the number of restricted stock units ("RSUs") vested on June 25, 2021.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 25, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 25, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F1 · derivative.underlying_shares: This amendment to the original Form 4 filed on June 29, 2021 is being filed to correct the number of restricted stock units ("RSUs") vested on June 25, 2021.

F1 · balance_after: This amendment to the original Form 4 filed on June 29, 2021 is being filed to correct the number of restricted stock units ("RSUs") vested on June 25, 2021.

SEC source: 0001209191-21-052810 · doc4a.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This amendment to the original Form 4 filed on June 29, 2021 is being filed to correct the number of restricted stock units ("RSUs") vested on June 25, 2021.

F2 · price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F1 · balance_after: This amendment to the original Form 4 filed on June 29, 2021 is being filed to correct the number of restricted stock units ("RSUs") vested on June 25, 2021.

SEC source: 0001209191-21-042454 · doc4.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700

Underlying: Common Stock · 700 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-21-042454 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

Underlying: Common Stock · 1,300 shares

Expires 2031-06-17

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 17, 2021 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-21-035008 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,800

SEC source: 0001209191-21-004833 · doc4.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,500

Underlying: Common Stock · 192,500 shares

Expires 2031-01-19

F4 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-21-004833 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,314

F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-20-065499 · doc4.xml · derivative · entry 5

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 130,821 shares

Expires 2021-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020.

F6 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable.

SEC source: 0001209191-20-065499 · doc4.xml · nonDerivative · entry 2

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,064

F1 · kind: This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-065499 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020.

F2 · balance_after: This total includes 2,275 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the Reporting Person on January 10, 2020 and are now owned directly by the Reporting Person.

SEC source: 0001209191-20-039195 · doc4.xml · derivative · entry 2

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,450

Underlying: Common Stock · 3,450 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date.

F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-20-039195 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,900

Underlying: Common Stock · 6,900 shares

Expires 2030-06-25

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the June 25, 2020 grant date (the "Grant Date"), subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-20-004814 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,000

Underlying: Common Stock · 349,000 shares

Expires 2030-01-21

F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 22, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-19-060691 · doc4.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2029-12-12

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 12, 2019 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-19-044967 · doc4.xml · derivative · entry 4

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,821

Underlying: Common Stock · 166,759 shares

Expires 2021-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable.

SEC source: 0001209191-19-044967 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,144

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.